ANPD002 / Aspen Neurosci - LARVOL DELTA

Aspen Neuroscience Announces Appointment of Damien McDevitt, PhD as President and Chief Executive Officer (PRNewswire) - "...I'm excited about our mission to develop transformational medicines for Parkinson's patients, who have very limited treatment options...including lead product ANPD001, currently undergoing IND-enabling studies for the treatment of sporadic forms of Parkinson's disease, and ANPD002, which combines gene correction and autologous neuron therapy, being studied for the treatment of genetic forms of Parkinson's disease."

Preclinical • CNS Disorders • Parkinson's Disease